Latest News | Lupin Launches Generic Drug in US for Postoperative Inflammation

New Delhi, Jan 9 (PTI) Drug maker Lupin on Tuesday said it has launched a generic medication for the treatment of postoperative inflammation in the US market.

The company has launched Bromfenac Ophthalmic Solution (0.07 per cent), after having received approval from the US Food and Drug Administration (USFDA), the Mumbai-based firm said in a regulatory filing.

Also Read | Kerala SET January 2024 Exam Admit Card: Hall Ticket for State Eligibility Test Examination Released at lbsedp.lbscentre.in, Know How To Download.

The company is the exclusive first-to-file for this product and is eligible for 180-day exclusivity, it added.

Bromfenac Ophthalmic Solution, 0.07 per cent, is the generic equivalent of Bausch & Lomb Inc's Prolensa ophthalmic solution, Lupin said.

Also Read | IIT JAM 2024 Exam: Admit Card for Joint Admission Test Examination To Be Released Soon at jam.iitm.ac.in, Know How To Download.

It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

As per the IQVIA MAT data, Bromfenac ophthalmic solution had estimated annual sales of USD 182 million in the US.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)